Expression and pharmacological evaluation of fusion protein FGF21-L-Fc

Yaoxue Xuebao

Volumn 46, Issue 7, 2011, Pages 787-792

  Yao, Wen Bing ^a   Ren, Gui Ping ^a   Han, Yang ^a   Cao, Hong Wei ^b   Gao, Hong Mei ^a   Kan, Fang Ming ^a   Wang, Qi ^a   Li, De Shan ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^b HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY   (China)

Author keywords

FGF21 L Fc; Glucose uptake; Stability

Indexed keywords

FC RECEPTOR; FIBROBLAST GROWTH FACTOR 21; GLUCOSE OXIDASE; HYBRID PROTEIN; IMMUNOGLOBULIN G4; RECOMBINANT FIBROBLAST GROWTH FACTOR;

ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; GLUCOSE TRANSPORT; IN VIVO STUDY; NONHUMAN; PROADIPOCYTE; PROTEIN EXPRESSION; PROTEIN STABILITY;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; ESCHERICHIA COLI; FIBROBLAST GROWTH FACTORS; GLUCOSE; IMMUNOGLOBULIN G; MALE; MICE; RECOMBINANT PROTEINS;

EID: 80052640204     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Nishimura T, Nakatake Y, Konishi M, et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver [J]. Biochim Biophys Acta, 2000, 1492: 203-206. (Pubitemid 30349198)
2. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator [J]. J Clin Invest, 2005, 115: 1627-1635. (Pubitemid 40814671)
3. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-221 [J]. Endocrinology, 2007, 148: 774-781. (Pubitemid 46143178)
4. Mai K, Schwarz F, Bobbert T, et al. Relation between fibroblast growth factor-21, adiposity, metabolism and weight reduction [J]. Metabolism, 2011, 60: 306-311.
5. Wente W, Efanov AM, Brenner M, et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways [J]. Diabetes, 2006, 55: 2470-2478. (Pubitemid 44871147)
6. Wang HY, Xiao YC, Fu LJ, et al. High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli [J]. BMC Biotechnol, 2010, 10: 14.
7. Petkova SB, Akilesh S, Sproule TJ, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease [J]. Int Immunol, 2006, 18: 1759-1769. (Pubitemid 44884038)
8. Jones TD, Hanlon M, Smith BJ, et al. The development of a modified human IFN-α2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection [J]. J Interferon Cytokine Res, 2004, 24: 560-572. (Pubitemid 39244545)
9. Zhang Y, Gao K, Han CM, et al. Study on methods and requirements for quality control of recombinant human tumor necrosis factor receptor Fc fusion protein [J]. Acta Pharm Sin, 2003, 38: 165-168.
10. Hou YT, Li JN, Ren GP, et al. Cloning, expression and glucose regulation activity of human FGF-21 [J]. Hereditas, 2010, 32: 583-587.
11. Ren GP, Hou YT, Jiang YY, et al. Efficient expression of soluble human FGF-21 and its glucose regulation activity [J]. Acta Pharm Sin, 2009, 44: 548-552.
12. Yang GZ, Gao XP, Yan JF, et al. Establishment of GOD-POD assay in a minimal way and application to glucose metabolism of 3T3 - L1 adipocyte and HepG2 cell in vitro [J]. Sichuan J Anat, 2003, 11: 12-15.
13. Wang HY. Establishment of the Animal Model of Type 2 Diabetes [D]. Changchun: Jilin University, 2007.
14. Jiang YY, Liu MY, Ren GP, et al. Cloning, expression and purification of mouse fibroblast growth factor-21 and its function in adipocyte glucose metabolism [J]. Prog Biochem Biophys, 2009, 36: 157-164.
15. Zhang HJ, Zhao JB, Li P. Progress in the study on animal model of diabetic nephropathy [J]. Chin Pharmacol Bull, 2008, 24: 845-848.
16. Kharitonenkov A, Shanafelt AB. FGF21: a novel prospect for the treatment of metabolic diseases [J]. Curr Opin Investig Drugs, 2009, 10: 359-364.
17. Rapaka RR, Goetzman ES, Zheng M, et al. Enhanced defense against Pneumocystis carinii mediated by a novel dectin-1 receptor Fc fusion protein [J]. J Immunol, 2007, 178: 3702-3712. (Pubitemid 46417638)
18. Greten TF, Korangy F, Neumann G, et al. Peptide-beta2-microglobulin -MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes [J]. J Immunol Methods, 2002, 271: 125-135. (Pubitemid 35346373)
19. Casares S, Zong CS, Radu DL, et al. Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation [J]. J Exp Med, 1999, 190: 543-553. (Pubitemid 29395382)
20. Calmels B, Paul S, Ziller C, et al. Secretomers as a new tool for the monitoring of CTL responses [J]. Cancer Immunol Immunother, 2005, 54: 548-556. (Pubitemid 40603194)
21. Carey B, DeLay M, Strasser JE, et al. A soluble divalent class I MHC/IgG1 fusion protein activates CD8+T cells in vivo [J]. Clin Immunol, 2005, 116: 65-76. (Pubitemid 40733584)
22. Romi F, Skeie GO, Vedeler C, et al. Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations [J]. J Neuroimmunol, 2000, 111: 169-176.
23. Mohammadi M, Olsen SK, Goetz R. A protein canyon in the FGF-FGF receptor dimer selects from an à la carte menu of heparan sulfate motifs [J]. Curr Opin Struct Biol, 2005, 15: 506-516. (Pubitemid 41393481)